Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifosfamide Schedules vs Doxorubicin in Advanced Soft Tissue Sarcoma
NCT00003212Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 1998
- Primary completion
- Nov 2001
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of ifosfamide in soft tissue sarcoma (STS) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression Free Survival Rate. Started Jan 1998; status: completed.
02
Drugs
ifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00003212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003212.